INTI · Inhibitor Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $340.6K | - | $377.8K | $325.6K | $236.1K | - | $319.6K | $239.8K | $235.4K | - |
| SG&A | $355.1K | - | $363.4K | $370.1K | $438.5K | - | $493.6K | $345.4K | $539.5K | - |
| Total Operating Expenses | $695.6K | - | $741.2K | $695.8K | $674.6K | - | $813.2K | $585.1K | $774.8K | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($695.6K) | - | ($741.2K) | ($695.8K) | ($674.6K) | - | ($813.2K) | ($585.1K) | ($774.8K) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($686.4K) | - | ($712.2K) | ($659.9K) | ($632.8K) | - | ($731.0K) | ($501.7K) | ($684.7K) | - |
| EPS - Basic | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 | - |
| EPS - Diluted | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.29M | $2.38M | $2.98M | $3.74M | $4.32M | $5.61M | $6.38M | $7.10M | $7.68M | $8.84M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $319.8K | $51.5K | $19.6K | $106.2K | $36.7K | $15.9K | $1.7K | $18.8K | $111.9K | $33.7K |
| Current Assets | $1.38M | $2.45M | $3.06M | $3.83M | $4.42M | $5.69M | $6.45M | $7.17M | $7.79M | $8.95M |
| Total Assets | $1.43M | $2.51M | $3.14M | $3.91M | $4.51M | $5.69M | $6.45M | $7.17M | $7.79M | $8.95M |
| Current Liabilities | $382.3K | $766.3K | $87.5K | $140.0K | $94.7K | $709.6K | $44.6K | $35.5K | $155.8K | $665.2K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.41M | $3.80M | $3.13M | $3.19M | $3.15M | $3.71M | $3.04M | $3.04M | $3.16M | $3.67M |
| Stockholders' Equity | ($1.98M) | ($1.29M) | $3.5K | $715.6K | $1.35M | $1.99M | $3.41M | $4.14M | $4.64M | $5.28M |
| Retained Earnings | ($56.11M) | ($55.42M) | ($54.12M) | ($53.41M) | ($52.75M) | ($52.12M) | ($50.70M) | ($49.97M) | ($49.46M) | ($48.78M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.08M) | - | - | - | ($1.28M) | - | - | - | ($1.16M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -47.9% | - | -22.7% | -16.9% | -14.0% | - | -11.3% | -7.0% | -8.8% | - |
| Return on equity | 34.7% | - | -20625.1% | -92.2% | -46.8% | - | -21.5% | -12.1% | -14.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.60 | 3.19 | 35.00 | 27.36 | 46.68 | 8.02 | 144.78 | 201.91 | 50.01 | 13.45 |
| Quick ratio | 3.60 | 3.19 | 35.00 | 27.36 | 46.68 | 8.02 | 144.78 | 201.91 | 50.01 | 13.45 |
| Cash ratio | 3.38 | 3.10 | 34.01 | 26.71 | 45.63 | 7.90 | 143.14 | 199.81 | 49.29 | 13.29 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.72 | -1.94 | 907.95 | 5.46 | 3.33 | 2.87 | 1.89 | 1.73 | 1.68 | 1.69 |
| Liabilities / Assets | 2.38 | 1.51 | 1.00 | 0.82 | 0.70 | 0.65 | 0.47 | 0.42 | 0.40 | 0.41 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -3.1% | - | 8.9% | -18.9% | 12.9% | - | -7.1% | 21.2% | -23.0% | - |
| Net income growth (YoY) | -8.5% | - | 2.6% | -31.5% | 7.6% | - | -10.0% | 23.4% | -26.9% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -99.9% | -82.7% | -70.8% | -62.4% | -47.2% | -41.8% | -40.2% | -36.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Inhibitor Therapeutics against the 5 most active filers in the same SIC group.